These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38457038)

  • 1. Safety of non-ionic contrast media in CT examinations for out-patients: retrospective multicenter analysis of 473,482 patients.
    Zeng W; Tang J; Xu X; Zhang Y; Zeng L; Zhang Y; Liang Z; Xia C; Zhao L; Li Z
    Eur Radiol; 2024 Sep; 34(9):5570-5577. PubMed ID: 38457038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical observation of the adverse drug reactions caused by non-ionic iodinated contrast media: results from 109,255 cases who underwent enhanced CT examination in Chongqing, China.
    Li X; Chen J; Zhang L; Liu H; Wang S; Chen X; Fang J; Wang S; Zhang W
    Br J Radiol; 2015 Mar; 88(1047):20140491. PubMed ID: 25582519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective analysis of non-laboratory-based adverse drug reactions induced by intravenous radiocontrast agents in a Joint Commission International-accredited academic medical center hospital in China.
    Chen QL; Zhao XY; Wang XM; Lv N; Zhu LL; Xu HM; Zhou Q
    Ther Clin Risk Manag; 2017; 13():565-573. PubMed ID: 28490883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-marketing surveillance study with iodixanol in 20 185 Chinese patients from routine clinical practices.
    Zhang BC; Hou L; Lv B; Xu YW
    Br J Radiol; 2014 Feb; 87(1034):20130325. PubMed ID: 24357597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Varied incidence of immediate adverse reactions to low-osmolar non-ionic iodide radiocontrast media used in computed tomography.
    Kim SR; Lee JH; Park KH; Park HJ; Park JW
    Clin Exp Allergy; 2017 Jan; 47(1):106-112. PubMed ID: 27648932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical observation of adverse drug reactions to non-ionic iodinated contrast media in population with underlying diseases and risk factors.
    Li X; Liu H; Zhao L; Liu J; Cai L; Liu L; Zhang W
    Br J Radiol; 2017 Feb; 90(1070):20160729. PubMed ID: 27928926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety aspects of iodinated contrast media related to their physicochemical properties: a pharmacoepidemiology study in two Tuscany hospitals.
    Lapi F; Cecchi E; Pedone C; Attanasio F; Banchelli G; Vannacci A; Di Pirro M; Moschini M; Berni V; Matucci R; Cini E; Scalia A; Tendi E; Mugelli A
    Eur J Clin Pharmacol; 2008 Jul; 64(7):723-37. PubMed ID: 18401577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of acute reactions to iopromide: postmarketing surveillance study of 74,717 patients.
    Kopp AF; Mortele KJ; Cho YD; Palkowitsch P; Bettmann MA; Claussen CD
    Acta Radiol; 2008 Oct; 49(8):902-11. PubMed ID: 18651252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the Radio-contrast Media-Induced Self-Reported Adverse Drug Reactions in a Tertiary Care Hospital of North India: A Prospective Study.
    Singh P; Gill MK; Kaur M; Mahajan R; Kaur M
    Int J Appl Basic Med Res; 2022; 12(1):14-17. PubMed ID: 35265475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of iopromide in patients undergoing cardiac catheterization: real-world multicenter experience with 17,513 patients from the TRUST trial.
    Chen JY; Liu Y; Zhou YL; Tan N; Zhang B; Chen PY; Chen LB
    Int J Cardiovasc Imaging; 2015 Oct; 31(7):1281-91. PubMed ID: 26058857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical safety evaluation of contrast agents based on real-world evidence.
    Jiang C; Li J; Huang Y; Huang D; Lin J; Jiang X
    J Clin Pharm Ther; 2021 Dec; 46(6):1600-1605. PubMed ID: 34293194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in Adverse Reactions Among Iodinated Contrast Media: Analysis of the KAERS Database.
    An J; Jung H; Kwon OY; Kang Y; Lee JH; Won HK; Song WJ; Kwon HS; Cho YS; Moon HB; Kim TB
    J Allergy Clin Immunol Pract; 2019; 7(7):2205-2211. PubMed ID: 30877072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-(2,3-dihydroxypropyl) carbamoyl side chain: a potentially significant factor for recurrent iodinated contrast medium-related adverse drug reactions.
    Kim PH; Suh CH; Jang EB; Kim S; Park KJ; Park HJ; Kim AY; Do KH; Lee JH; Kim JH; Jung AY; Lee CW
    Eur Radiol; 2024 Oct; 34(10):6444-6453. PubMed ID: 38625610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse Drug Reactions to Radiographic Contrast Media in a Teaching Hospital in North India: An Observational Study.
    Chopra D; Jain A; Garg R; Dhingra S
    Curr Drug Saf; 2019; 14(2):122-126. PubMed ID: 30666915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of the incidence of hypersensitivity reactions and post-contrast acute kidney injury after ioversol in more than 57,000 patients: part 1-intravenous administration.
    van der Molen AJ; Dekkers IA; Bedioune I; Darmon-Kern E
    Eur Radiol; 2022 Aug; 32(8):5532-5545. PubMed ID: 35312790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immediate hypersensitivity reactions to IV non-ionic iodinated contrast in computed tomography.
    Ho J; Kingston RJ; Young N; Katelaris CH; Sindhusake D
    Asia Pac Allergy; 2012 Oct; 2(4):242-7. PubMed ID: 23130329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and severity of nonionic low-osmolar iodinated contrast medium-related adverse drug reactions in the Republic of Korea: Comparison by generic.
    Jang EB; Suh CH; Kim PH; Kim AY; Do KH; Lee JH; Gwon DI; Jung AY; Lee CW
    Medicine (Baltimore); 2023 May; 102(19):e33717. PubMed ID: 37171360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and diagnostic image quality of iopromide: results of a large non-interventional observational study of European and Asian patients (IMAGE).
    Palkowitsch P; Lengsfeld P; Stauch K; Heinsohn C; Kwon ST; Zhang SX; Liang CH
    Acta Radiol; 2012 Mar; 53(2):179-86. PubMed ID: 22184683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse drug reactions for CAM and conventional drugs detected in a network of physicians certified to prescribe CAM drugs.
    Tabali M; Ostermann T; Jeschke E; Witt CM; Matthes H
    J Manag Care Pharm; 2012; 18(6):427-38. PubMed ID: 22839683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of serious adverse drug reactions as cause of emergency department visit in children: a 5-years active pharmacovigilance study.
    Lombardi N; Crescioli G; Bettiol A; Marconi E; Vitiello A; Bonaiuti R; Calvani AM; Masi S; Lucenteforte E; Mugelli A; Giovannelli L; Vannacci A
    BMC Pharmacol Toxicol; 2018 Apr; 19(1):16. PubMed ID: 29661234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.